Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.
Lopes A, Vandermeulen G, Préat V. · 2019
Read Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. by Lopes A, Vandermeulen G, Préat V. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6449928.txt.
Description
Lopes and co-authors review DNA vaccines against cancer, covering five years of lab work and ten years of human trials. Plasmid vaccines proved safe and could raise broad, aimed immune responses, yet the braking defenses inside tumors kept the clinical gains modest. Two lines of attack organize the field's answers.
The first tunes the vaccine itself: picking better antigens, adding neoantigens unique to a tumor, and polishing the plasmid. The second pairs the shot with partners that lift the brakes in the tumor's neighborhood or grow immune cell numbers, from helper proteins to checkpoint blockade. Details matter; one popular helper also draws in braking cells. Winning approval as standard care remains the unfinished goal.
Catalog record
| CREATOR | Lopes A, Vandermeulen G, Préat V. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |